Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients.
D000380:Agranulocytosis / Q000150:complications*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000150:complications; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D008297:Male; D009070:Moxalactam / Q000009:adverse effects / Q000627:therapeutic use*; D009254:Nafcillin / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D011897:Random Allocation; D014031:Tobramycin / Q000008:administration & dosage* / Q000009:adverse effects
D009254:Nafcillin; D009070:Moxalactam; D014031:Tobramycin